Congestive Heart Failure
Congestive heart failure (CHF) is a chronic, progressive condition in which the heart is unable to supply sufficient blood and oxygen to the body. It can result from conditions that weaken the heart muscle, cause stiffening of the heart muscles, or increase oxygen demand by the body tissues beyond the heart’s capability.
Heart disease is the leading cause of death worldwide, with CHF affecting an estimated 1% of the Western world, including over six million Americans. There is no cure, and medications and surgical treatments only seek to relieve symptoms and slow further damage.
Research, however, suggests that protein phosphatase inhibitor 1 ( I-1c) is down-regulated in failing hearts. Gene therapy to express an active form of I-1c may improve heart function and provide a new approach to treating CHF.
Visit the National Institutes of Health’s website to learn more about Congestive Heart Failure.
CHF Advocacy Partners
We are fortunate to work with patient advocacy groups, as well as leading researchers, scientists and medical professionals to bring new therapeutics for CHF into the clinic.
Clinical Trials
Many who can benefit from promising gene therapeutics face a significantly altered way of life. Many of these diseases are progressive. Thus, time is of the essence and the importance of every clinical trial has greater meaning to all of us at RhiaPharmaceutical.
